This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Evaluate Imatinib in Desmoid Tumors

This study has been completed.
Information provided by (Responsible Party):
Bernd Kasper, Heidelberg University Identifier:
First received: June 2, 2010
Last updated: May 2, 2017
Last verified: May 2017
The objective of the present study is to evaluate the activity and safety of imatinib in patients with aggressive fibromatosis who, after receiving the standard therapy, show an inoperable recurrent tumor or disease not readily controllable by surgery or radiotherapy.

Condition Intervention Phase
Aggressive Fibromatosis Desmoid Tumor Drug: Imatinib Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study to Evaluate Glivec (Imatinib Mesylate) to Induce Progression Arrest in Aggressive Fibromatosis / Desmoid Tumors Not Amenable to Surgical Resection With R0 Intent or Accompanied by Unacceptable Function Loss

Resource links provided by NLM:

Further study details as provided by Bernd Kasper, Heidelberg University:

Primary Outcome Measures:
  • Non-progression rate after 6 months of treatment [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Non-progression rate after 12 and 24 months of treatment [ Time Frame: 12 and 24 months ]
  • Response rate [ Time Frame: 12 and 24 months ]
  • Progression-free survival (PFS) and overall survival (OS) [ Time Frame: 12 and 24 months ]
  • Recording of patient quality of life [ Time Frame: 12 and 24 months ]

Enrollment: 39
Study Start Date: June 2010
Study Completion Date: December 2016
Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: drug
Imatinib 800 mg
Drug: Imatinib
800 mg
Other Name: Glivec


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with histological confirmed aggressive fibromatosis (desmoid tumor)
  • Measurable disease according to the RECIST criteria
  • Evidence of relapse or disease progression within the last 6 months (based on RECIST criteria) in computed tomography or magnetic resonance imaging
  • No possibility of complete surgical resection or cases in which surgical therapy leaving a large tissue defect, functional deficit or disfigurement would be required
  • No possibility of curative radiotherapy with acceptable toxicity and/or late morbidity
  • Previous treatment of the tumor region by surgical intervention and/or radiotherapy and/or antihormonal therapy possible
  • Age > or = 18 years
  • WHO PS < or = 1
  • Effective contraception during study medication
  • Signed informed consent form

Exclusion Criteria:

  • Surgical intervention < 4 weeks
  • Prior therapy with imatinib
  • Pregnancy or lactation
  • Severe hepatic dysfunction
  • Known allergic reaction to imatinib or one of its components
  • The following laboratory values: Absolute neutrophil count < 1.5 x 103/mm3, Platelets < 100,000/mm3, Serum creatinine > or = 2.5 mg/dl, SGOT and/or SGPT > 2.5 x ULN (upper limit of normal), Total bilirubin > 1.5 x ULN
  • Participation in another study (four weeks before and during the study)
  • Prior malignancy apart from completely resected basal cell carcinoma of the skin or carcinoma in situ of the uterine cervix
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01137916

University of Heidelberg, Mannheim University Medical Center
Mannheim, Germany, 68167
Sponsors and Collaborators
Heidelberg University
Principal Investigator: Bernd Kasper, PD Dr. med. University of Heidelberg, Mannheim University Medical Center
  More Information

Additional Information:
Responsible Party: Bernd Kasper, PD Dr. med., Heidelberg University Identifier: NCT01137916     History of Changes
Other Study ID Numbers: CSTI571BDE70
Study First Received: June 2, 2010
Last Updated: May 2, 2017

Additional relevant MeSH terms:
Fibromatosis, Aggressive
Behavioral Symptoms
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017